|
Market Cap | 2.19B | EPS (ttm) | 3.18 |
P/E | 25.19 | EPS this Y | 8.08% |
Forward P/E | 63.23 | EPS next Y | 20.99% |
PEG | 503.77 | EPS past 5Y | - |
P/S | 9.62 | EPS next 5Y | 0.05% |
P/B | 9.53 | EPS Q/Q | 2063.02% |
Dividend | - | Sales Q/Q | 21.33% |
Insider Own | 5.28% | Inst Own | 91.65% |
Insider Trans | -55.14% | Inst Trans | -0.43% |
Short Float | 2.03% | Earnings | May 13/a |
Analyst Recom | 1.00 | Target Price | 100.00 |
Avg Volume | 180.14K | 52W Range | 62.00 - 91.61 |
|
|
|
Agilysys, Inc. operates as a technology company. It offers innovative software for point-of-sale, payment gateway, reservation and table management, guest offers management, property management, inventory and procurement, analytics, document management, and mobile and wireless solutions and services to the hospitality industry. The firm also serves the gaming industry for both corporate and tribal, hotels resort and cruise, foodservice management, and the restaurant, university, and healthcare sectors. The company was founded in 1963 and is headquartered in Alpharetta, GA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
SRINIVASAN RAMESH | President & CEO | Mar 10 '24 | Option Exercise | 76.53 | 11,309 | 865,478 | 643,060 | Mar 11 06:57 PM | KEATING MELVIN L | Director | Mar 05 '24 | Buy | 75.95 | 100 | 7,596 | 44,039 | Mar 07 04:39 PM | KEATING MELVIN L | Director | Feb 20 '24 | Buy | 77.62 | 300 | 23,287 | 43,939 | Feb 22 04:41 PM | MAK CAPITAL ONE LLC | 10% Owner | Feb 14 '24 | Sale | 82.59 | 867,729 | 71,665,738 | 2,060,458 | Feb 16 07:41 PM | Wood William David III | Chief Financial Officer | Jan 29 '24 | Sale | 85.45 | 10,000 | 854,500 | 50,391 | Jan 31 05:04 PM |
|
|
|
|
Market Cap | 933.18M | EPS (ttm) | - |
P/E | - | EPS this Y | 59.72% |
Forward P/E | - | EPS next Y | 36.78% |
PEG | - | EPS past 5Y | -48.47% |
P/S | 0.50 | EPS next 5Y | - |
P/B | 0.73 | EPS Q/Q | - |
Dividend | 7.10% | Sales Q/Q | 1.56% |
Insider Own | 2.58% | Inst Own | 46.96% |
Insider Trans | 10.81% | Inst Trans | - |
Short Float | 1.72% | Earnings | May 13/a |
Analyst Recom | 1.56 | Target Price | 15.78 |
Avg Volume | 833.11K | 52W Range | 12.63 - 14.90 |
|
|
|
American Healthcare REIT, Inc. operates as a real estate investment trust/REIT. It invests in a diversified portfolio of real estate properties, focusing primarily on medical office buildings, hospitals, skilled nursing facilities, senior housing and other healthcare-related facilities. The company was founded on January 23, 2015 and is headquartered in Irvine, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Streiff Mathieu B. | Director | Feb 09 '24 | Buy | 12.00 | 83,333 | 999,996 | 90,740 | Feb 13 08:40 PM | Prosky Danny | CEO & President | Feb 09 '24 | Buy | 12.00 | 83,333 | 999,996 | 305,555 | Feb 13 08:20 PM |
|
|
|
|
Market Cap | 203.45M | EPS (ttm) | -1.49 |
P/E | - | EPS this Y | 41.35% |
Forward P/E | - | EPS next Y | 37.54% |
PEG | - | EPS past 5Y | -37.60% |
P/S | 2.11 | EPS next 5Y | - |
P/B | 3.76 | EPS Q/Q | 55.71% |
Dividend | - | Sales Q/Q | 24.83% |
Insider Own | 56.63% | Inst Own | 29.62% |
Insider Trans | -0.13% | Inst Trans | 3.88% |
Short Float | 4.73% | Earnings | May 13/a |
Analyst Recom | 1.38 | Target Price | 9.00 |
Avg Volume | 164.12K | 52W Range | 3.04 - 8.80 |
|
|
|
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. The company was founded by Garry Nolan, Yury Goltsev and Nikolay Samusik in 2015 and is headquartered in Marlborough, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
McKelligon Brian | President and CEO | Mar 20 '24 | Option Exercise | 0.30 | 7,500 | 2,272 | 239,368 | Mar 22 05:54 PM | McKelligon Brian | President and CEO | Mar 20 '24 | Sale | 4.97 | 7,500 | 37,243 | 231,868 | Mar 22 05:54 PM | McKelligon Brian | President and CEO | Mar 13 '24 | Sale | 4.94 | 7,500 | 37,035 | 224,368 | Mar 14 08:41 PM | McKelligon Brian | President and CEO | Dec 19 '23 | Option Exercise | 0.30 | 7,500 | 2,272 | 160,063 | Dec 20 07:16 PM | McKelligon Brian | President and CEO | Dec 19 '23 | Sale | 4.48 | 7,500 | 33,566 | 152,563 | Dec 20 07:16 PM |
|
|
| |
|
Market Cap | 495.09M | EPS (ttm) | -2.09 |
P/E | - | EPS this Y | 21.14% |
Forward P/E | - | EPS next Y | 5.90% |
PEG | - | EPS past 5Y | 22.18% |
P/S | 3094.30 | EPS next 5Y | 1.00% |
P/B | 0.84 | EPS Q/Q | 22.55% |
Dividend | - | Sales Q/Q | -55.32% |
Insider Own | 34.30% | Inst Own | 59.28% |
Insider Trans | -0.03% | Inst Trans | 5.02% |
Short Float | 30.20% | Earnings | May 13/a |
Analyst Recom | 1.69 | Target Price | 12.08 |
Avg Volume | 2.13M | 52W Range | 2.23 - 6.89 |
|
|
|
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Jan 30 '24 | Buy | 3.60 | 190 | 683 | 819,590 | Mar 06 09:52 PM | MESSEMER DEBORAH M. | Director | Dec 18 '23 | Sale | 2.70 | 18,640 | 50,317 | 62,456 | Dec 20 04:26 PM | Mayo Stephen | Director | Aug 07 '23 | Sale | 4.29 | 10,000 | 42,855 | 25,328 | Aug 09 04:07 PM |
|
|
|
|
Market Cap | 37.16M | EPS (ttm) | -2.02 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 18.24% |
P/S | 0.09 | EPS next 5Y | - |
P/B | 0.61 | EPS Q/Q | -8772.38% |
Dividend | - | Sales Q/Q | 15.58% |
Insider Own | 25.86% | Inst Own | 44.56% |
Insider Trans | 0.00% | Inst Trans | 1.44% |
Short Float | 3.59% | Earnings | May 13/a |
Analyst Recom | 3.00 | Target Price | 5.00 |
Avg Volume | 30.05K | 52W Range | 1.81 - 4.00 |
|
|
|
Ampco-Pittsburgh Corp. is engaged in the manufacture and sale of custom designed engineering products. It operates through the Forged and Cast Engineered Products, and Air and Liquid Processing segments. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls and open-die forged products. Forged hardened steel rolls are used primarily in cold rolling mills by producers of steel, aluminum and other metals. The Air and Liquid Processing segment includes the Aerofin, Buffalo Air Handling, and Buffalo Pumps divisions. The company was founded in 1929 and is headquartered in Carnegie, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
McNair Darrell L | Director | Sep 13 '23 | Buy | 3.12 | 3,000 | 9,360 | 6,640 | Sep 20 12:46 PM | DiSanto Frederick D. | Director | Jun 29 '23 | Buy | 2.99 | 7,399 | 22,123 | 47,177 | Jul 03 11:41 AM | DiSanto Frederick D. | Director | Jun 28 '23 | Buy | 2.85 | 918 | 2,616 | 39,778 | Jul 03 11:41 AM | DiSanto Frederick D. | Director | Jun 23 '23 | Buy | 2.94 | 2,000 | 5,880 | 38,860 | Jun 26 11:35 AM | DiSanto Frederick D. | Director | Jun 22 '23 | Buy | 2.94 | 5,000 | 14,700 | 36,860 | Jun 26 11:35 AM |
|
|
| |
|
Market Cap | 114.59M | EPS (ttm) | -0.44 |
P/E | - | EPS this Y | -13.64% |
Forward P/E | - | EPS next Y | 32.50% |
PEG | - | EPS past 5Y | 62.58% |
P/S | 2.55 | EPS next 5Y | - |
P/B | 4.88 | EPS Q/Q | 38.77% |
Dividend | - | Sales Q/Q | 44.90% |
Insider Own | 10.23% | Inst Own | 74.70% |
Insider Trans | 27.11% | Inst Trans | 0.68% |
Short Float | 3.84% | Earnings | May 13/a |
Analyst Recom | 1.00 | Target Price | 6.10 |
Avg Volume | 379.87K | 52W Range | 2.22 - 6.25 |
|
|
|
Augmedix, Inc. engages in the development of software that converts natural clinician-patient conversations into medical documentation. It offers live support including referrals, orders, and reminders that allow clinicians to focus on patient care. The company was founded by Ian Shakil in 2012 and is headquartered in San Francisco, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Shakil Ian | CHIEF STRATEGY OFFICER | Apr 15 '24 | Option Exercise | 0.86 | 500 | 430 | 3,500 | Apr 16 09:07 PM | Shakil Ian | CHIEF STRATEGY OFFICER | Apr 15 '24 | Sale | 3.80 | 500 | 1,900 | 3,000 | Apr 16 09:07 PM | Shakil Ian | CHIEF STRATEGY OFFICER | Apr 12 '24 | Option Exercise | 0.86 | 19,544 | 16,808 | 22,544 | Apr 15 09:15 PM | Shakil Ian | CHIEF STRATEGY OFFICER | Apr 12 '24 | Sale | 3.82 | 19,544 | 74,590 | 3,000 | Apr 15 09:15 PM | Shakil Ian | CHIEF STRATEGY OFFICER | Apr 11 '24 | Option Exercise | 0.86 | 24,778 | 21,309 | 27,778 | Apr 11 08:30 PM |
|
|
|
|
Market Cap | 194.80M | EPS (ttm) | -0.42 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 2.92 | EPS next 5Y | - |
P/B | - | EPS Q/Q | -8.75% |
Dividend | - | Sales Q/Q | -0.40% |
Insider Own | 0.00% | Inst Own | 2.31% |
Insider Trans | - | Inst Trans | - |
Short Float | 0.37% | Earnings | May 13/a |
Analyst Recom | - | Target Price | - |
Avg Volume | 20.43K | 52W Range | 3.80 - 9.19 |
|
|
|
Bridger Aerospace Group Holdings, Inc. engages in the provision of aerial wildfire surveillance, relief and suppression, and aerial firefighting services using next-generation technology and environmentally friendly and sustainable firefighting methods. Its fleet includes Daher Kodiak 100, Twin Commander, Pilatus PC-12, DeHaviland Twin Otter 300, and De Havilland CL-415EAF. The company was founded by Timothy Sheehy and Matthew P. Sheehey in 2014 and is headquartered in Belgrade, MT. |
|
| |
|
Market Cap | 6.02M | EPS (ttm) | -38.01 |
P/E | - | EPS this Y | 98.91% |
Forward P/E | - | EPS next Y | 65.62% |
PEG | - | EPS past 5Y | 59.23% |
P/S | 0.12 | EPS next 5Y | 20.00% |
P/B | - | EPS Q/Q | 94.24% |
Dividend | - | Sales Q/Q | -3.99% |
Insider Own | 4.05% | Inst Own | 4.47% |
Insider Trans | 0.00% | Inst Trans | 1.35% |
Short Float | 0.91% | Earnings | May 13/a |
Analyst Recom | 1.00 | Target Price | 1.63 |
Avg Volume | 5.84M | 52W Range | 0.13 - 32.09 |
|
|
|
BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1984 and is headquartered in Lake Forest, CA. |
|
|
|
Market Cap | 775.95M | EPS (ttm) | 0.35 |
P/E | 35.53 | EPS this Y | 52.78% |
Forward P/E | 10.77 | EPS next Y | 177.98% |
PEG | - | EPS past 5Y | - |
P/S | 1.71 | EPS next 5Y | - |
P/B | 2.57 | EPS Q/Q | 101.28% |
Dividend | - | Sales Q/Q | 48.38% |
Insider Own | 50.95% | Inst Own | 19.42% |
Insider Trans | 0.00% | Inst Trans | 137.30% |
Short Float | 0.87% | Earnings | May 13/a |
Analyst Recom | 1.00 | Target Price | 20.25 |
Avg Volume | 52.68K | 52W Range | 10.10 - 14.20 |
|
|
|
Bioceres Crop Solutions Corp. engages in the provision of crop productivity solutions. The firm includes seeds, seed traits, seed treatments, biologicals, high-value adjuvants and fertilizers. It operates through the following segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment deals with the development and commercialization of integrated products that combine three complementary components biotechnological events, germplasm and seed treatments in order to increase crop productivity and create value for customers. The Crop Protection segment develops and produces adjuvants, insecticides and fungicides. The Crop Nutrition segment focuses on the development, production and commercialization of inoculants that allow the biological fixation of nitrogen in the crops and of fertilizers including bio fertilizers and micro granulated fertilizers that increases the productivity and yield of the crops. The company was founded on November 14, 2017 and is headquartered in Rosario, Argentina. |
|
|
|
Market Cap | 85.97M | EPS (ttm) | -0.85 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 0.29 | EPS next 5Y | 47.50% |
P/B | 0.71 | EPS Q/Q | 89.96% |
Dividend | - | Sales Q/Q | -43.80% |
Insider Own | 13.50% | Inst Own | 8.27% |
Insider Trans | -2.23% | Inst Trans | - |
Short Float | 7.52% | Earnings | May 13/a |
Analyst Recom | 3.00 | Target Price | 4.00 |
Avg Volume | 1.28M | 52W Range | 0.64 - 3.20 |
|
|
Today 04:37PM
|
BuzzFeed, Inc. First Quarter 2024 Financial Results in Line With March Outlook
(Business Wire) |
01:59PM
|
Stocks to Watch Monday: GameStop, AMC, Incyte, Kraft Heinz
(The Wall Street Journal) |
May-02-24 11:30AM
|
BuzzFeed, Inc. Announces 1-For-4 Reverse Stock Split
(Business Wire) |
Apr-22-24 04:30PM
|
BuzzFeed, Inc. to Release First Quarter 2024 Financial Results on Monday, May 13, 2024
(Business Wire) |
Apr-16-24 12:18PM
|
A reverse stock split is BuzzFeed's last hope of staying listed on the Nasdaq
(Quartz) -6.19% |
10:58AM
|
BZFD Stock: BuzzFeed Is Prepping for a Reverse Stock Split
(InvestorPlace) |
Mar-28-24 10:04AM
|
The Independent and BuzzFeed Sign Long-Term License and Strategic Partnership in UK & Ireland
(Business Wire) +17.01% |
Mar-27-24 11:24AM
|
BuzzFeed, Inc. (NASDAQ:BZFD) Q4 2023 Earnings Call Transcript
(Insider Monkey) |
Mar-26-24 12:50PM
|
Stocks to Watch Tuesday: Trump Media, GameStop, BuzzFeed, Tesla
(The Wall Street Journal) |
Mar-25-24 09:52PM
|
BZFD Stock Earnings: BuzzFeed Misses Revenue for Q4 2023
(InvestorPlace) +9.11% |
|
Buzzfeed, Inc. is an independent digital media company, which engages in engagement, distribution, and leveraging data. Its cross-platform network includes BuzzFeed Originals, which creates articles, lists, quizzes, and videos, BuzzFeed Media Brands, which consists of a portfolio of identity-driven lifestyle brands including Nifty, Goodful, As/Is, and Tasty, a social food network, BuzzFeed Studios, which produces original content across broadcast, cable, SVOD, film and digital platforms, and BuzzFeed News and HuffPost, which include reporting and investigative journalism, and BuzzFeed Commerce, which develops products and experiences, as well as licensing and other strategic partnerships. The company was founded by Jonah Peretti and John Johnson in November 2006 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Rolle Janet L | Director | Apr 29 '24 | Option Exercise | 0.00 | 76,910 | 0 | 363,993 | May 01 05:59 PM | Rothstein Adam | Director | Apr 29 '24 | Option Exercise | 0.00 | 415,318 | 0 | 2,247,222 | May 01 06:00 PM | COLEMAN GREGORY | Director | Apr 29 '24 | Option Exercise | 0.00 | 76,910 | 0 | 1,081,649 | May 01 05:59 PM | Acharia Angela | Director | Apr 29 '24 | Option Exercise | 0.00 | 76,910 | 0 | 276,975 | May 01 05:59 PM | Arroyo David | CLO | Mar 08 '24 | Option Exercise | 0.00 | 2,812 | 0 | 46,659 | Mar 12 08:18 PM |
|
|
|